Companies: Mirna
The data also indicate early signs of clinical activity in certain patients.
NEW YORK (GenomeWeb) – Researchers from Mirna Therapeutics this month published new animal data demonstrating the potential of combining two tumor-suppressing microRNA mimics for the treatment of non-small cell lung cancer (NSCLC).
Mirna Therapeutics this week announced interim data from its ongoing Phase I trial of MRX34, a microRNA mimic designed to treat cancer, which showed the drug to have a "manageable safety profile."
Voyager Therapeutics, a startup developing adeno-associated viral vector therapies, including RNAi-based ones, for central nervous system disorders, has named Dinah Sah as its senior vice president of neuroscience.
Marina Biotech and Mirna Therapeutics this week announced that they have amended an existing licensing agreement to give Mirna greater access to Marina's Smarticle liposomal delivery technology for use with microRNA-based therapeutics.
Oct 3, 2013
Aug 8, 2013
Jun 6, 2013
People in the News: Sinil Kim
Premium
May 2, 2013
Jan 31, 2013
People in the News: Clay Siegall
Premium
Nov 15, 2012
Oct 4, 2012
Jan 5, 2012
Nov 17, 2011
Oct 27, 2011
Jul 21, 2011
Jun 16, 2011
People in the News: Jun 16, 2011
Premium
Apr 7, 2011
Mar 24, 2011
Jan 20, 2011
Jan 20, 2011